Rosuvastatin restored adrenergic and nitrergic function in mesenteric arteries from obese rats

British Journal of Pharmacology

Volumn 162, Issue 1, 2011, Pages 271-285

  Blanco Rivero, Javier ^a   De Las Heras, Natalia ^b   Martín Fernández, Beatriz ^b   Cachofeiro, Victoria ^b   Lahera, Vicente ^b   Balfagón, Gloria ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

adrenergic innervation; nitrergic innervation; obesity; statins

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NORADRENALIN; ROSUVASTATIN; TRIACYLGLYCEROL;

ADRENERGIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; ELECTRIC FIELD; ELECTROSTIMULATION; LIPID DIET; MALE; MESENTERIC ARTERY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ADENOSINE TRIPHOSPHATE; ANIMALS; BLOTTING, WESTERN; CALCITONIN GENE-RELATED PEPTIDE; ELECTRIC STIMULATION; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MESENTERIC ARTERIES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; NOREPINEPHRINE; OBESITY; PYRIMIDINES; RATS; RATS, WISTAR; SULFONAMIDES;

EID: 78650115989     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01030.x     Document Type: Article

References (44)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Balfagón G, Márquez-Rodas I, Alvarez Y, Alonso MJ, Cachofeiro V, Salaices M, et al. (2004). Aldosterone modulates neural vasomotor response in hypertension: role of calcitonin gene-related peptide. Regul Pept 120: 253-260.
3. Belin de Chantemèle EJ, Vessières E, Guihot AL, Toutain B, Loufrani L, Henrion D, (2010). Cyclooxygenase-2 preserves flow-mediated remodelling in old obese Zucker rat mesenteric arteries. Cardiovasc Res 86: 516-525.
4. Boeckxstaens GE, Pelckmans PA, (1997). Nitric oxide and the non-adrenergic non-cholinergic neurotransmission. Comp Biochem Physiol A Physiol 118: 925-937.
5. Brock JA, Tan JH, (2004). Selective modulation of noradrenaline release by alpha 2-adrenoceptor blockade in the rat-tail artery in vitro. Br J Pharmacol 142: 267-274.
6. Cachofeiro V, Goicochea M, De Vinuesa SG, Oubiña P, Lahera V, Luño J, (2008). Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 111: 4-9.
7. Del Campo L, Ferrer M, Balfagón G, (2009). Hypertension alters the function of nitrergic and sensory innervation in mesenteric arteries from female rats. J Hypertens 27: 791-799.
8. Chen YX, Wang XQ, Fu Y, Yao YJ, Kong MY, Nie RQ, et al. (2009). Pivotal role of inflammation in vascular endothelial dysfunction of hyperlipidemic rabbit and effects by atorvastatin. Int J Cardiol [Epub ahead of print].
9. Devaraj S, Chan E, Jialal I, (2006). Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 91: 4489-4496.
10. Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, et al. (2005). Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 66: 462-471.
11. Dunn WR, Brock JA, Hardy TA, (1999). Electrochemical and electrophysiological characterization of neurotransmitter release from sympathetic nerves supplying rat mesenteric arteries. Br J Pharmacol 128: 174-180.
12. Elmarakby AA, Imig JD, (2010). Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. Clin Sci (Lond) 118: 291-301.
13. Ferrer M, Encabo A, Marín J, Balfagón G, (1992). Vasoconstrictive effects of angiotensin I and II in cat femoral arteries. Role of endothelium. Gen Pharmacol 23: 1171-1175.
14. Ferrer M, Alonso MJ, Salaices M, Marín J, Balfagón G, (2000a). Increase in neurogenic nitric oxide metabolism by endothelin-1 in mesenteric arteries from hypertensive rats. J Cardiovasc Pharmacol 36: 541-547.
15. Ferrer M, Marín J, Balfagon G, (2000b). Diabetes alters neuronal nitric oxide release from rat mesenteric arteries. Role of protein kinase C. Life Sci 66: 337-345.
16. Ferrer M, Alonso MJ, Salaices M, Marín J, Balfagón G, (2001). Angiotensin II increases neurogenic nitric oxide metabolism in mesenteric arteries from hypertensive rats. Life Sci 68: 1169-1179.
17. Ferrer M, Sánchez M, Minoves N, Salaices M, Balfagón G, (2003). Aging increases neuronal nitric oxide release and superoxide anion generation in mesenteric arteries from spontaneously hypertensive rats. J Vasc Res 40: 509-519.
18. Ferrer M, Sánchez M, Martín MC, Márquez-Rodas I, Alonso MJ, Salaices M, et al. (2004). Protein kinase A increases electrical stimulation-induced neuronal nitric oxide release in rat mesenteric artery. Eur J Pharmacol 487: 167-173. (Pubitemid 38368994)
19. Gelosa P, Cimino M, Pignieri A, Tremoli E, Guerrini U, Sironi L, (2007). The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag 3: 567-577.
20. Guzik TJ, Korbut R, Adamek-Guzik T, (2003). Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54: 469-487.
21. Hatanaka Y, Hobara N, Honghua J, Akiyama S, Nawa H, Kobayashi Y, et al. (2006). Neuronal nitric-oxide synthase inhibition facilitates adrenergic neurotransmission in rat mesenteric resistance arteries. J Pharmacol Exp Ther 316: 490-497.
22. De Las Heras N, Martín-Fernández B, Miana M, Ballesteros S, Oubiña MP, López-Farré AJ, et al. (2009). The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance. J Hypertens 27: 37-41.
23. Iwatani Y, Kosugi K, Isobe-Oku S, Atagi S, Kitamura Y, Kawasaki H, (2008). Endothelium removal augments endothelium-independent vasodilatation in rat mesenteric vascular bed. Br J Pharmacol 154: 32-40.
24. Javeshghani D, Schiffrin EL, Sairam MR, Touyz RM, (2009). Potentiation of vascular oxidative stress and nitric oxide-mediated endothelial dysfunction by high-fat diet in a mouse model of estrogen deficiency and hyperandrogenemia. J Am Soc Hypertens 3: 295-305.
25. Katragadda S, Arora RR, (2010). Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects. Am J Ther 17: 11-23.
26. Kawasaki H, Takasaki K, Saito A, Goto K, (1988). Calcitonin gene related peptide acts as a novel vasodilator neurotransmitter in mesenteric resistance vessels of the rat. Nature 335: 164-167.
27. Khamaisi M, Søndergaard M, Segev Y, Dagnaes-Hansen F, Jensen TG, Landau D, et al. (2007). Differential effects on kidney and liver growth of a non-viral hGH-expression vector in hypophysectomized mice. Growth Horm IGF Res 17: 279-287.
28. Landsberger M, Jantzen F, Könemann S, Felix SB, (2005). Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells. Biochem Biophys Res Commun 336: 1005-1009.
29. Li YJ, Duckles SP, (1992). Effect of endothelium on the actions of sympathetic and sensory nerves in the perfused rat mesentery. Eur J Pharmacol 210: 23-30.
30. Marín J, Balfagón G, (1998). Effect of clenbuterol on non-endothelial nitric oxide release in rat mesenteric arteries and the involvement of β-adrenoceptors. Br J Pharmacol 124: 473-478.
31. Marín J, Ferrer M, Balfagon G, (2000). Role of protein kinase C in electrical-stimulation-induced neuronal nitric oxide release in mesenteric arteries from hypertensive rats. Clin Sci (Lond) 99: 277-283.
32. Miâdi-Messaoud H, Chouchane A, Abderrazek E, Debbabi H, Zaouali-Ajina M, Tabka Z, et al. (2010). Obesity-induced impairment of endothelium-dependent vasodilation in Tunisian women. Int J Obes (Lond) 34: 273-279.
33. Minoves N, Balfagón G, Ferrer M, (2002). Role of female sex hormones in neuronal nitric oxide release and metabolism in rat mesenteric arteries. Clin Sci (Lond) 103: 239-247.
34. Nielsen KC, Owman C, (1971). Contractile response and amine receptor mechanisms in isolated middle cerebral artery of the cat. Brain Res 27: 33-42.
35. Otto A, Fontaine D, Fontaine J, Berkenboom G, (2005). Rosuvastatin treatment protects against nitrate-induced oxidative stress. J Cardiovasc Pharmacol 46: 177-184.
36. Prior LJ, Eikelis N, Armitage JA, Davern PJ, Burke SL, Montani JP, et al. (2010). Exposure to a high-fat diet alters leptin sensitivity and elevates renal sympathetic nerve activity and arterial pressure in rabbits. Hypertension 55: 862-868.
37. Rueda-Clausen CF, Lahera V, Calderon J, Bolivar IC, Castillo VR, Gutierrez M, et al. (2010). The presence of abdominal obesity is associated with changes in vascular function independently of other cardiovascular risk factors. Int J Cardiol 139: 32-41.
38. Schäfer A, Fraccarollo D, Eigenthaler M, Tas P, Firnschild A, Frantz S, et al. (2005). Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol 25: 1071-1077.
39. Scherrer U, Randin D, Tappy L, Vollenweider P, Jéquier E, Nicod P, (1994). Body fat and sympathetic nerve activity in healthy subjects. Circulation 89: 2634-2640.
40. Straznicky NE, Eikelis N, Lambert EA, Esler MD, (2008). Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep 10: 440-447.
41. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS, (2002). Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87: 563-568.
42. Williams TD, Chambers JB, Roberts LM, Henderson RP, Overton JM, (2003). Diet-induced obesity and cardiovascular regulation in C57BL/6J mice. Clin Exp Pharmacol Physiol 30: 769-778.
43. Xavier FE, Salaices M, Márquez-Rodas I, Alonso MJ, Rossoni LV, Vassallo DV, et al. (2004). Neurogenic nitric oxide release increases in mesenteric arteries from ouabain hypertensive rats. J Hypertens 22: 949-957.
44. Xu KZ, Zhu C, Kim MS, Yamahara J, Li Y, (2009). Pomegranate flower ameliorates fatty liver in an animal model of type 2 diabetes and obesity. J Ethnopharmacol 123: 280-287.